QC
MLTX icon

Quadrature Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Quadrature Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
+109,204
New +$1.98M 0.02% 483
2026
Q1 		– Sell
-50,217
Closed -$662K – 1678
2025
Q4 		$662K Buy
+50,217
New +$593K 0.01% 621

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quadrature Capital's MLTX Position: Q2 2026 in Review

Quadrature Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 109,204 shares worth $2.13M. The stake represents 0.02% of the portfolio and ranks #483 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in MLTX as recently as Q4 2025.

Quadrature Capital first reported a position in MLTX in Q4 2025 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Quadrature Capital held 109,204 shares of MoonLake Immunotherapeutics worth $2.13M as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Quadrature Capital position in Q2 2026.
  • MoonLake Immunotherapeutics made up 0.02% of Quadrature Capital's portfolio in Q2 2026, its #483 holding.
  • Quadrature Capital first reported a position in MoonLake Immunotherapeutics in Q4 2025 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.